首页> 外文期刊>The Journal of Urology >Stage pT0 after radical prostatectomy with previous positive biopsy sets: a multicenter study.
【24h】

Stage pT0 after radical prostatectomy with previous positive biopsy sets: a multicenter study.

机译:多中心研究:根治性前列腺切除术后先前有活检阳性的pT0期:多中心研究。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: We analyzed preoperative data, pathological results and followup of pT0 tumors after radical prostatectomy for prostate cancer diagnosed on previous positive biopsy. MATERIALS AND METHODS: At 6 centers a total of 30 of 7,693 radical prostatectomy specimens were classified as pT0 despite prior biopsy proven prostate cancer. No patients were diagnosed after transurethral prostate resection or received neoadjuvant hormonal treatment. All biopsy cores and radical prostatectomy specimens were reanalyzed by a second pathologist. Followup comprised clinical examination and postoperative prostate specific antigen assay at 1 and 3 months, and every 6 months thereafter. RESULTS: Median patient age was 63 years (range 46 to 73). Median preoperative prostate specific antigen was 7.4 ng/ml (range 1.3 to 23). Of the cases 24 were T1c and 6 were T2a. The median number of biopsy cores was 10 (range 6 to 21) with 1 positive (range 1 to 4). On biopsies median tumor length was 1 mm (range 0.3 to 18) and there was tumor in 11.1% (range 3.4% to 64%). In 25 cases (83.3%) there was only 1 positive biopsy. Gleason score was 3 + 3 in 23 cases and less than 6 in 5 with grade 4 in 2. Only 9 cases filled all nonsignificant tumor criteria. Median specimen weight was 61 gm (range 40 to 160). At a median 82-month followup (range 14 to 226) there was no biochemical progression. CONCLUSIONS: After biopsy proven cancer pT0 prostate cancer is an unpredictable pathological finding. Despite its excellent prognosis it has medicolegal repercussions that justify DNA based tissue analysis. There is no evidence that finding focal cancer after extensive prostate resection changes patient prognosis and postoperative treatment.
机译:目的:我们分析了前列腺癌根治术前经活检确诊的pT0肿瘤的术前数据,病理结果和随访情况。材料与方法:尽管有活检证明前列腺癌,但在6个中心的7693例前列腺癌根治术中,有30例被分类为pT0。经尿道前列腺切除术或新辅助激素治疗均无患者被诊断出。第二位病理学家对所有活检核心和前列腺癌根治术标本进行了重新分析。随访包括在1和3个月以及之后每6个月进行临床检查和术后前列腺特异性抗原测定。结果:患者中位年龄为63岁(范围46至73)。术前前列腺特异性抗原的中位数为7.4 ng / ml(范围1.3至23)。在这些案例中,有24个是T1c,有6个是T2a。活检核心的中位数为10个(范围6到21),其中1个阳性(范围1-4)。活检中,肿瘤的中位长度为1 mm(范围为0.3至18),肿瘤的发生率为11.1%(范围为3.4%至64%)。 25例(83.3%)中只有1例活检阳性。 Gleason评分在23例中为3 + 3,在5级中小于6,其中2级为4。只有9例符合所有非重要的肿瘤标准。标本重量的中位数为61 gm(范围为40至160)。在82个月的中位随访(范围从14到226)中,没有生化进展。结论:活检证实为癌症的pT0前列腺癌是不可预测的病理发现。尽管预后良好,但仍具有法医学意义,可以证明基于DNA的组织分析。没有证据表明广泛的前列腺切除术后发现局灶性癌症会改变患者的预后和术后治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号